Fusen Pharmaceutical Company Limited has called its annual general meeting (AGM) for 29 May 2026 at 2:00 p.m. at Units 5906–5912, 59/F, The Center, 99 Queen’s Road Central, Hong Kong.

Key resolutions:

1. Financial Statements: Shareholders will consider and adopt the audited consolidated results and directors’ and auditors’ reports for the financial year ended 31 December 2025.

2. Board Re-elections & Remuneration: The meeting will vote on the re-election of executive directors Mr Cao Zhiming and Ms Meng Qingfen, and independent non-executive directors Mr Lee Kwok Tung, Louis and Mr Yu Ho Ming. The board will also be authorised to determine directors’ remuneration.

3. Auditor Re-appointment: Ratification is sought to re-appoint Messrs. CCTH CPA Limited as external auditors and to authorise the board to set their remuneration.

4. General Issuance Mandate: Directors are requesting authority to allot, issue or deal with additional shares and/or convertible securities, and to sell or transfer treasury shares, up to 20% of the company’s issued share capital (excluding any treasury shares) during the mandate period.

5. Share Repurchase Mandate: Approval is sought to repurchase up to 10% of the company’s issued shares (excluding any treasury shares) on the Hong Kong Stock Exchange or other recognised exchanges within the same mandate period.

6. Mandate Extension: Conditional on the above mandates being approved, the share issuance limit may be increased by the number of shares repurchased under the buy-back mandate, effectively allowing total potential issuance of up to an additional 10% of the company’s issued shares.

Administrative details:

• Shareholders must lodge transfer documents with Computershare Hong Kong Investor Services Limited by 4:30 p.m. on 22 May 2026 to qualify for AGM attendance and voting. • The register of members will be closed from 26 May 2026 to 29 May 2026, inclusive.

Chairman and CEO Mr Cao Zhiming signed the notice on 30 April 2026 on behalf of the board.